title: Oxaliplatin: a new drug for the treatment of metastatic carcinoma of the colon or rectum.
abstract: Oxaliplatin is a useful agent in combination with 5-fluorouracil/leucovorin for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed during or within 6 months of completion of first-line therapy (a combination of bolus 5-fluorouracil/leucovorin and irinotecan). Oxaliplatin works by disrupting DNA replication and transcription and is cell-cycle nonspecific. In vitro, oxaliplatin has shown activity against numerous tumor lines, but it has only been approved for the treatment of metastatic carcinoma of the colon or rectum.
authors.affiliation: College of Pharmacy, Washington State University, Spokane, WA, USA.
authors.forename: Danial E
authors.initials: DE
authors.lastname: Baker
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077150:Oxaliplatin; D011358:Product Surveillance, Postmarketing; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin